Dry powder Inhalation of lytic mycobacteriophages for adjunct therapy in a mouse model of infection with Mycobacterium tuberculosis
Authors:
- 11 March 2025
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 152, 102631
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- India Ministry of Science & Technology Department of Biotechnology (5/8/5/38/2019-ECD-I)
- Indian Council of Medical Research (51/2024/AM)
- Indian Institute of Science Education and Research Pune
- Central Drug Research Institute
This publication has 47 references indexed in Scilit:
- Mycobacteriophages: therapeutic approach for mycobacterial infectionsDrug Discovery Today, 2024
- Nano/microformulations for Bacteriophage Delivery2023
- Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translationClinical Microbiology and Infection, 2023
- Approaches for manufacture, formulation, targeted delivery and controlled release of phage-based therapeuticsCurrent Opinion in Biotechnology, 2021
- Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical reviewMedicinal Research Reviews, 2019
- Repurposing of gamma interferon via inhalation deliveryAdvanced Drug Delivery Reviews, 2018
- Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosisAdvanced Drug Delivery Reviews, 2016
- Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory InfectionsPharmaceutical Research, 2016
- A hand-held apparatus for “nose-only” exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophagesEuropean Journal of Pharmaceutical Sciences, 2008
- Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of CapreomycinPharmaceutical Research, 2007